Search Results
May 19, 2026, 07:00 ET BioLineRx and Hemispherian Announce New GLIX1 Data Demonstrating Potent Anti-Tumor Effect in Glioblastoma (GBM) Across Multiple In-Vivo Studies, Including a Temozolomide (TMZ)-Resistant Model with Patient-Derived Xenografts
progressive GBM and other high-grade gliomas. The primary objective is to establish a maximum tolerated dose (MTD) and/or a recommended dose based on safety, PK/PD and preliminary efficacy. Updates to the Phase 1/2a trial are anticipated during H2 2026, with full results on the dose escalation part expected in
More news about: BioLineRx Ltd.; Hemispherian AS
May 18, 2026, 20:00 ET Accro Bioscience Announces $50 Million Series C Financing Led by OrbiMed to Advance Clinical Pipeline for Immune Mediated Diseases
cell death and inflammation. AC-101 has completed Phase I studies in healthy volunteers in Australia and China, demonstrating a favorable safety and PK/PD profile. A Phase Ib/IIa proof-of-concept study in Chinese patients with moderate-to-severe UC has been completed. The Company has received the IND
More news about: Accro Bioscience Inc.
May 18, 2026, 20:00 ET Innovent Showcased Clinical and Preclinical Results of Next-Generation Autoimmune and Ophthalmology Pipeline at the 2026 ATS and ARVO Conferences
effectively suppressed the expansion of orbital adipose and muscular tissues. In Pharmacokinetics & Pharmacodynamics (PK/PD) Studies in Non-Human Primates (NHPs), IBI3031 demonstrated a superior PK profile compared to existing SoCs. These results suggest a potential for extended dosing intervals, which will
More news about: Innovent Biologics
May 18, 2026, 10:00 ET Major breakthrough of Sanyou Biopharmaceuticals AI-STAL
QualityAI-driven optimization comprehensively covers:HumanizationAffinity maturationDevelopability enhancementPK optimizationTaking affinity maturation as an example, AI integrates structural simulation, molecular docking, alanine scanning, and virtual
More news about: Sanyou Bio
May 18, 2026, 09:15 ET Bambusa Therapeutics Presents Positive Preliminary Phase 1 BBT002 Data at American Thoracic Society 2026 (ATS 2026) International Conference and Announces First Patient Dosed in Phase 1b/2a CRSwNP Trial
sustained inhibition of pSTAT6 for at least 8 weeks following a single dose compared to baseline.Pharmacokinetics (PK): BBT002 exhibited prolonged PK with a half-life of approximately 29.4 days at or above target exposure following a single dose, supporting the potential for extended
More news about: Bambusa Therapeutics, Inc.
May 15, 2026, 06:59 ET Global Diethyl Ketone Market Outlook 2026-2036: Pharmaceutical Demand Accelerates Growth for Dow Inc., Arkema S.A., and Mitsui Chemicals
CorporationRelated Reports: Polyketone (PK) Market: https://www.futuremarketinsights.com/reports/polyketone-pk-marketDiethyl Sulfate Market:
More news about: Future Market Insights
May 14, 2026, 09:00 ET Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth Phase
CCR8 Treg depleter, and are encouraged given our previously reported clinical data including anti-tumor activity, safety data, tumor biomarker data and PK data.""Casdozokitug is the only known clinical stage IL-27 antagonist, and the first line HCC study in combination with LOQTORZI is now fully
More news about: Market News Updates
May 14, 2026, 07:30 ET Galmed Announces Results from First-in-Man Pharmacokinetics Study of Oral Formulation of Aramchol Meglumine (AM); 400mg AM Increases Bioavailability by ~500% in Comparison to Aramchol Free Acid (AA) 300mg
a clinical-stage biopharmaceutical company for liver disease and GI oncological therapeutics, announced today major milestone results from a Phase 1 PK study in healthy subjects (Study AM-001). The overall objective of the study was to identify the dose of Aramchol meglumine (AM) administered once
More news about: Galmed Pharmaceuticals Ltd.
May 13, 2026, 08:44 ET American Heritage Schools Celebrates Class of 2026 for Earning Coast-to-Coast Acceptances to the Nation's Top Universities
American Heritage Schools:American Heritage Schools is a nationally recognized private, college-preparatory day school for students in PK3-12th grades, known for academic excellence and top rankings across multiple disciplines. With two 40-acre campuses, one in Broward County and another
More news about: American Heritage Schools
May 07, 2026, 16:04 ET California's Teacher Supply Reaches Decade High as State Workforce Investments Yield Promising Results
credentials were issued in 2024-25, a 16% year-over-year increase in the number of newly issued Multiple Subject, Single Subject, Education Specialist, and PK-3 Early Childhood Education Specialist teaching credentials.The 2024-25 data mark the second consecutive year of growth in new teaching credentials
More news about: California Commission on Teacher Credentialing
May 05, 2026, 14:48 ET Public Knowledge® Acquires Programs from Civic Dinners, Inc. to Expand Team Communication and Leadership Services
they make decisions. These programs help teams put that into practice in their daily work." Workplace Culture Conversations has been part of the PK IMPACT Leadership™ workshop at Public Knowledge® since 2024. The acquisition allows the firm to further integrate both offerings across leadership
More news about: Public Knowledge
May 04, 2026, 07:00 ET AVISTA HEALTHCARE PARTNERS LAUNCHES BIRCHWELL CONSUMER HEALTH AS NEW OVER-THE-COUNTER PLATFORM; ACQUIRES BAG BALM AS FIRST INVESTMENT
investing in and building consumer healthcare platforms, including WellSpring Consumer Healthcare, a leading U.S. platform of established OTC brands; PK Consumer Health, a European consumer healthcare platform with a portfolio of market‑leading VMS brands; Cooper Consumer Health, a market‑leading consumer
More news about: Avista Healthcare Partners
May 04, 2026, 07:00 ET GRIN Therapeutics' Pivotal Phase 3 Beeline Study Initiated in Europe
(ClinicalTrials.gov identifier: NCT06392009) is an ongoing, open-label Phase 1b/2a clinical trial assessing the safety, tolerability, pharmacokinetics (PK), and potential efficacy of radiprodil in patients with TSC or FCD type II. About GRIN Therapeutics GRIN Therapeutics, Inc. is dedicated
More news about: GRIN Therapeutics Inc.
May 01, 2026, 09:00 ET Amy's Kitchen Lands Costco Distribution in Three Major Markets, Bringing Organic Frozen Meals to Millions of Members
plant-forward meals into a format designed for real life. The Cheese Enchiladas and Bean & Cheese Burritos join Amy's Medium Chili 6pk and the Vegetable Lasagna 6pk, each with varied regional club availability.To learn more about Amy's Kitchen, visit
More news about: Amy's Kitchen
May 01, 2026, 00:23 ET Kodiak Sciences to Present Pipeline Advances and KSI-101 Clinical Data, Including Results from a MESI Cohort in a Tertiary Care Uveitis Practice, at Upcoming Scientific Conferences
cohort.1.Title: Bispecific Trap-Antibody Inhibiting Interleukin-6 and Vascular Endothelial Growth Factor (KSI-101): Clinical PK/PD Cohort in Asian Patients with Macular Edema Secondary to Inflammation (MESI)Poster Session: Clinical features and treatment outcomes
More news about: Kodiak Sciences Inc.
Apr 29, 2026, 16:05 ET Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
4Q26.VK2735 Maintenance Dosing Study Advances; Data Expected 3Q26. Based on VK2735's promising efficacy and differentiated pharmacokinetic (PK) profile, the company is evaluating a range of novel dosing regimens for both the induction and the long-term maintenance of weight loss. Providing flexible
More news about: Viking Therapeutics, Inc.
Apr 28, 2026, 21:00 ET Insilico's Rentosertib Inhalation Solution Receives IND Clearance for the World's First AI-Driven Candidate to Enter Direct-to-Lung Clinical Study
Following positive Phase IIa results for oral Rentosertib in GENESIS-IPF with good tolerability, a favorable PK profile, and dose-dependent efficacy improvements, the inhalation solution has received IND clearance from the CDE.The inhalation solution is designed for targeted
More news about: Insilico Medicine
Apr 28, 2026, 08:30 ET Bucking the Trend: HKEYBIO Slashes NHP Autoimmune Model Prices Amidst Global Monkey Shortage
QualityHKEYBIO's "Contrarian Promotion" is designed to help innovative drug developers generate the critical efficacy and pharmacokinetic (PK/PD) data, as well as clinical predictive biomarker analysis, needed for clinical transitions without exceeding their budgets. Key features of
More news about: HKeyBio
Apr 28, 2026, 07:00 ET BioLineRx and Hemispherian Announce First Patient Dosed in Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)
progressive GBM and other high-grade gliomas. The objective is to establish a maximum tolerated dose (MTD) and/or a recommended dose based on safety, PK/PD and preliminary efficacy. Data from the Phase 1 part of the trial are anticipated in H1 2027.The Phase 2a expansion part of the trial is planned
More news about: BioLineRx Ltd.; Hemispherian AS
Apr 27, 2026, 08:00 ET Stealth BioTherapeutics to Present Clinical Data for Bevemipretide Eye Drops at the Association for Research in Vision and Ophthalmology 2026 Annual Meeting
topical bevemipretide (1%, 2%, or 3%) or vehicle, randomized by participant to their trial eye or fellow eye. After each cohort, safety assessments and PK samples will be analyzed to determine the dosing regimen for Part B, which consists of three MAD cohorts of eight participants each, randomized in a
More news about: Stealth BioTherapeutics Inc.
Apr 27, 2026, 08:00 ET RedHill Biopharma Announces Full-Year 2025 Financial Results and Operational Highlights
U.S. Phase 3 & 2 results in gastroenteritis/gastritis and diarrhea-predominant irritable bowel syndrome (IBS-D) respectively, a positive comparative PK clinical study as part of the oncology support (CINV/RINV) program12, plus decades of ondansetron clinical use (>22 million annual U.S.
More news about: RedHill Biopharma Ltd.
Apr 21, 2026, 22:10 ET Ractigen Therapeutics Presents Positive Phase I Data for RAG-17 in SOD1-ALS at the 2026 AAN Annual Meeting, Demonstrating 81% Reduction in Neurofilament Light Chain
randomized, double-blind, placebo-controlled, multiple ascending dose (MAD) study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of repeated intrathecal injections of RAG-17 in patients with SOD1 mutations. Since the first participant
More news about: Ractigen Therapeutics
Apr 21, 2026, 22:00 ET Total Investment of Approx. USD 8.5 Million in Malaria and NTD R&D Projects With Partners Including MMV, GSK, Tanabe Pharma, Eisai and DNDi
continue to determine the efficacy of MMV172 in the primate model of relapsing P. vivax malaria to develop an understanding of the anti-hypnozoite PK/PD relationship required to determine if MMV172 also meets the dose criterion for SERCAP (Single Encounter Radical Cure and Prophylaxis) or, if necessary,
More news about: GHIT Fund
Apr 21, 2026, 22:00 ET Total Investment of Approx. USD 8.5 Million in Malaria and NTD R&D Projects With Partners Including MMV, GSK, Tanabe Pharma, Eisai and DNDi
continue to determine the efficacy of MMV172 in the primate model of relapsing P. vivax malaria to develop an understanding of the anti-hypnozoite PK/PD relationship required to determine if MMV172 also meets the dose criterion for SERCAP (Single Encounter Radical Cure and Prophylaxis) or, if necessary,
More news about: GHIT Fund
Apr 21, 2026, 16:05 ET Jazz Pharmaceuticals to Present Data at ASCO 2026 Highlighting Advancements for Ziihera® (zanidatamab-hrii) in Gastroesophageal Adenocarcinoma and Zepzelca® (lurbinectedin)
number: 8014Safety andpharmacokinetics (PK)of lurbinectedin (lurbi)in pediatric patients(pts) withrelapsed/refractory(R/R) solid tumors andpreliminary
More news about: Jazz Pharmaceuticals plc